Humacyte Shares Owned By Institutions vs. Market Capitalization

HUMA Stock  USD 4.52  0.12  2.73%   
Based on the measurements of profitability obtained from Humacyte's financial statements, Humacyte may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Humacyte's ability to earn profits and add value for shareholders. As of November 30, 2024, Price To Sales Ratio is expected to decline to 96.95. In addition to that, Days Sales Outstanding is expected to decline to 7.90. At present, Humacyte's Accumulated Other Comprehensive Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 6 M, whereas Operating Income is forecasted to decline to (105 M).
For Humacyte profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Humacyte to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Humacyte utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Humacyte's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Humacyte over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.34)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.53)
Return On Equity
(8.51)
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Humacyte Market Capitalization vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Humacyte's current stock value. Our valuation model uses many indicators to compare Humacyte value to that of its competitors to determine the firm's financial worth.
Humacyte is rated below average in shares owned by institutions category among its peers. It is rated below average in market capitalization category among its peers creating about  19,327,994  of Market Capitalization per Shares Owned By Institutions. At present, Humacyte's Market Cap is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Humacyte's earnings, one of the primary drivers of an investment's value.

Humacyte Market Capitalization vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Humacyte

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
30.09 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Humacyte

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
581.58 M
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Humacyte Market Capitalization vs Competition

Humacyte is rated below average in market capitalization category among its peers. Market capitalization of Health Care industry is currently estimated at about 24.28 Billion. Humacyte holds roughly 581.58 Million in market capitalization claiming about 2.4% of equities under Health Care industry.
Capitalization  Valuation  Total debt  Workforce  Revenue

Humacyte Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Humacyte, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Humacyte will eventually generate negative long term returns. The profitability progress is the general direction of Humacyte's change in net profit over the period of time. It can combine multiple indicators of Humacyte, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-100 M-105 M
Income Before Tax-110.8 M-116.3 M
Total Other Income Expense Net-10.7 M-10.2 M
Net Loss-13.8 M-14.4 M
Net Loss-110.8 M-116.3 M
Net Interest Income-774 K-812.7 K
Interest Income5.7 MM
Net Loss-89.4 M-84.9 M
Income Tax Expense3.1 M3.3 M
Non Operating Income Net Other90.6 M75.8 M
Change To Netincome-63 M-59.8 M
Net Loss(1.07)(1.12)
Income Quality 0.66  0.63 
Net Loss(6.17)(5.86)

Humacyte Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Humacyte. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Humacyte position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Humacyte's important profitability drivers and their relationship over time.

Use Humacyte in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Humacyte position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Humacyte will appreciate offsetting losses from the drop in the long position's value.

Humacyte Pair Trading

Humacyte Pair Trading Analysis

The ability to find closely correlated positions to Humacyte could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Humacyte when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Humacyte - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Humacyte to buy it.
The correlation of Humacyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Humacyte moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Humacyte moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Humacyte can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Humacyte position

In addition to having Humacyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corona Opportunity Thematic Idea Now

Corona Opportunity
Corona Opportunity Theme
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:
Check out Risk vs Return Analysis.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
To fully project Humacyte's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Humacyte at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Humacyte's income statement, its balance sheet, and the statement of cash flows.
Potential Humacyte investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Humacyte investors may work on each financial statement separately, they are all related. The changes in Humacyte's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Humacyte's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.